Bayer Healthcare has bolstered its biologics drive after acquired German biotech company Direvo Biotech for €210 million.

The move will see Bayer’s biologics division significantly strengthened by integrating Direvo’s R&D personnel into Bayer Schering Pharma’s global drug discovery organisation.

“Today Bayer Schering Pharma is among the top ten biologicals companies in the world. We are committed to further strengthen out biologicals portfolio, and Direvo’s leadership in protein engineering provides promising opportunities for further business growth,” said Arthur Higgins, Chief Executive of Bayer Healthcare.

Under the terms of the agreement, Direvo’s Cologne site will be maintained and integrated in Bayer Schering Pharma as a centre of expertise for biologicals alongside the global R&D centres in Germany and the US.

Direvo has a protein engineering platform that uses high throughput technologies for the rapid discovery and optimisation of biopharmaceuticals. The platform has already been applied to therapeutic antibodies and proteases that will also be added to the preclinical pipeline of Bayer Schering Pharma.